Background/Objectives: The escalating incidence of cesarean deliveries has driven an increase in cesarean scar pregnancy (CSP). Given the risks of hemorrhage and uterine rupture, surgical intervention is recommended; however, the optimal modality remains unclear. This systematic review and network meta-analysis (NMA) evaluated the efficacy and safety of surgical and combined techniques for CSP management. Methods: Following PRISMA guidelines and PROSPERO registration, electronic databases were searched from January 2010 onwards. Eligible studies included randomized controlled trials and cohort studies (≥5 patients) evaluating primary uterus-preserving surgical interventions for CSP. A frequentist NMA calculated pooled odds ratios (OR) and mean differences (MD), with treatments ranked via surface under the cumulative ranking (SUCRA) curves. Results: Sixty-four studies (8970 women; 63 non-randomized, one randomized) were included. Combined hysteroscopic-laparoscopic surgery (COMB_HL) ranked highest for initial treatment success (SUCRA = 93.5%; OR vs. dilation and curettage [DC] = 6.05, 95% CI: 2.50–14.65), followed by high-intensity focused ultrasound plus curettage (HIFU_C) (SUCRA = 79.1%), laparoscopic resection (70.6%), and ultrasound-guided sclerotherapy plus curettage (64.5%). Methotrexate plus curettage was not statistically distinguishable from DC (OR = 0.71, 95% CI: 0.35–1.46). Blood loss (MD = −39.92 mL) and hospital stay (MD = −1.00 day) favoured advanced modalities, but heterogeneity was very high (I2 = 95.0% and 96.7%) and both prediction intervals crossed the null. HIFU_C reduced overall complications versus DC (OR = 0.23, 95% CI: 0.07–0.72). Reproductive outcomes were too sparsely reported for synthesis. Evidence certainty was low for treatment success and very low for secondary safety endpoints. Conclusions: The available observational evidence suggests that visually guided and combined modalities are associated with a higher probability of success than blind DC. Rankings are hypothesis-generating rather than proof of superiority; treatment should be individualized to CSP type, residual myometrial thickness, gestational age, fertility wishes and local expertise.
No takes yet. Share an insight, caveat, or question.
Alshehri et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: